Compare LEG & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEG | DVAX |
|---|---|---|
| Founded | 1883 | 1996 |
| Country | United States | United States |
| Employees | 17700 | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | 2004 |
| Metric | LEG | DVAX |
|---|---|---|
| Price | $12.30 | $15.41 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $10.50 | ★ $26.50 |
| AVG Volume (30 Days) | 1.7M | ★ 4.9M |
| Earning Date | 02-12-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $4,172,899,999.00 | $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | N/A | $15.85 |
| P/E Ratio | $7.49 | ★ N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $6.48 | $9.20 |
| 52 Week High | $12.09 | $15.49 |
| Indicator | LEG | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 75.23 | 88.47 |
| Support Level | $10.78 | $10.78 |
| Resistance Level | $11.84 | $15.45 |
| Average True Range (ATR) | 0.31 | 0.10 |
| MACD | 0.06 | 0.15 |
| Stochastic Oscillator | 97.55 | 98.41 |
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.